Table 6. Clinical trials of oral fluconazole and terbinafine in the treatment of canine Malassezia dermatitis Study Drug Design Dose used Clinical outcome Adverse effects Comment LoE Sickafoose et al. Fluconazole RCT-B (13 dogs 5-10 mg/kg once 8/13 >50 % 6/13 dogs: Concurrent 2 2010[384] received FCZ + daily clinical transient cefalexin therapy cefalexin) improvement vomiting [n=4], limits vomiting and interpretation. soft [n=1], Compared with KTZ diarrhoea [n=1] + cefalexin. Rosales et al. Terbinafine RCT-B (8 dogs 30 mg/kg ponce 3/8 >50 % clinical Nil Small group sizes 2 2005 [148] received daily improvement and concurrent terbinafine + cefalexin therapy cefalexin) limits interpretation. Compared with KTZ + cefalexin. Berger et al. Terbinafine RCT-B (10 dogs 30 mg/kg once 8/10 >50% Mild signs in Small group sizes; 2 2012[429] received daily OR clinical 3/10 dogs in two dosing intervals terbinafine at improvement in both groups compared. 30 mg/kg on 2 either dose) both groups (overall 6/20); Complete clinical consecutive vomiting [n=2], resolution in only days/week, for diarrhoea [n=2], 3/20 dogs at d21. 21 days anorexia [n=1], Eight dogs panting [n=1]. developed Elevated ALT in 1 pyoderma during dog. study.
Table 6. Clinical trials of oral fluconazole and terbinafine in the treatment of canine Malassezia dermatitis Study Drug Design Dose used Clinical outcome Adverse effects Comment LoE Sickafoose et al. 2010[384] Fluconazole RCT-B (13 dogs received FCZ + cefalexin) 5-10 mg/kg once daily 8/13 >50 % clinical improvement 6/13 dogs: transient vomiting [n=4], vomiting and soft [n=1], diarrhoea [n=1] Concurrent cefalexin therapy limits interpretation. Compared with KTZ + cefalexin. 2 Rosales et al. 2005 [148] Terbinafine RCT-B (8 dogs received terbinafine + cefalexin) 30 mg/kg ponce daily 3/8 >50 % clinical improvement Nil Small group sizes and concurrent cefalexin therapy limits interpretation. Compared with KTZ + cefalexin. 2 Berger et al. 2012[429] Terbinafine RCT-B (10 dogs received terbinafine at either dose) 30 mg/kg once daily OR 30 mg/kg on 2 consecutive days/week, for 21 days 8/10 >50% clinical improvement in both groups Mild signs in 3/10 dogs in both groups (overall 6/20); vomiting [n=2], diarrhoea [n=2], anorexia [n=1], panting [n=1]. Elevated ALT in 1 dog. Small group sizes; two dosing intervals compared. Complete clinical resolution in only 3/20 dogs at d21. Eight dogs developed pyoderma during study. 2